	US 12,226,427 B2
	Treatment for gene reactivation
Nissim Benvenisty, Jerusalem (IL); and Dan Vershkov, Jerusalem (IL)
Assigned to YISSUM RESEARCH DEVELOPMENT COMPANY OF THE HEBREW UNIVERSITY OF JERUSALEM LTD., Jerusalem (IL)
Appl. No. 17/268,655
Filed by YISSUM RESEARCH DEVELOPMENT COMPANY OF THE HEBREW UNIVERSITY OF JERUSALEM LTD., Jerusalem (IL)
PCT Filed Aug. 15, 2019, PCT No. PCT/IL2019/050917 § 371(c)(1), (2) Date Feb. 16, 2021, PCT Pub. No. WO2020/035866, PCT Pub. Date Feb. 20, 2020.
Claims priority of provisional application 62/719,060, filed on Aug. 16, 2018.
Prior Publication US 2021/0169908 A1, Jun. 10, 2021
Int. Cl. A61K 31/706 (2006.01); A61K 31/437 (2006.01); A61P 25/00 (2006.01)

CPC A61K 31/706 (2013.01) [A61K 31/437 (2013.01); A61P 25/00 (2018.01)]

19 Claims

1. A method of reactivating transcription of a fragile X mental retardation 1 (FMR1) gene in a cell, comprising contacting said cell with 5-aza-2-deoxycytidine (5-azadC) and 3-Deazaneoplanocin A (DZNep), thereby reactivating transcription of said FMR1 gene in said cell.